FSD Pharma To Forfeit Cannabis License, Liquidate FV Pharma To Focus On Coronavirus

FSD Pharma (CSE: HUGE) (NASDAQ: HUGE) this morning announced that it is going all in on the ongoing coronavirus pandemic, and as a result, is closing down its FV Pharma subsidiary. FV Pharma currently holds a Health Cannabis license to cultivate cannabis, which it intends to forfeit.

FSD Pharma Logo

Specifically, the company has notified Health Canada that it will forfeit the license and suspend all cannabis related activity within 30 days. All related cannabis assets are in the process of being liquidated, which includes the sale of the firms production facility in Cobourg, Ontario.

In making the decision, CEO Raza Bokhari commented that shareholder value is, “best servied in closing down our medicinal grade cannabis operation .. and reinforcing steps to advance pharmaceutical R&D efforts on our lead compound FSD201.” The company currently intends to submit an investigational new drug application to the FDA for the use of this compound in the treatment of COVID-19.

The announcement marks the end of what was considered a highly controversial operation when it comes to the cannabis space. The Deep Dive covered the story extensively, from the questionable size and scale of the facility, to the share consolidation that effectively wiped many shareholders out. It appears that the controversy was not without merit, given that the company has now walked away from its cannabis aspirations entirely.

FSD Pharma last traded at $5.03 on the CSE.


Information for this briefing was found via Sedar, and FSD Pharma. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Newmont Q2 Earnings: Setting The Tone For This Earnings Cycle

Highest Grade Antimony Mine in the World!? | James Atkinson – Antimony Resources

Gold/Silver: People Can Still Lose Money In This Bull Market!? | Rick Rule

Recommended

Nova Scotia Bans Forest Access to Prevent Wildfires

Cardiol Therapeutics Releases Positive Topline Results From Phase II Clinical Trial

Related News

US COVID-19 Cases Climb by 1 Million in Just 14 Days as Pandemic Spirals Out of Control

According to the latest data compiled by Johns Hopkins University, coronavirus infections in the US...

Tuesday, November 3, 2020, 10:03:29 AM

Steven Mnuchin: Those Receiving $2 Million Or More Under PPP To Be Audited

As part of the CARES Act, the US federal government unveiled the Paycheck Protection Program...

Wednesday, April 29, 2020, 02:17:00 PM

FSD Pharma Approved To List on Nasdaq

FSD Pharma (CSE: HUGE) is going to the big leagues. The firm announced this morning...

Monday, December 16, 2019, 07:37:45 AM

Revive Files Clinical Trial Application With Health Canada, Releases Phase 3 FDA Study Design For Potential Treatment Of COVID-19

Revive Therapeutics (CSE: RVV) continues to advance its clinical trial efforts. The company announced this...

Wednesday, June 3, 2020, 11:30:38 AM

FSD Pharma Announces 1 for 201 Share Consolidation

FSD Pharma (CSE: HUGE) announced this morning that it will be completing a share consolidation...

Friday, October 11, 2019, 09:04:28 AM